問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



Taipei Veterans General Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • 112Taipei CityBeitou

Recruiting Trial

901Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

2252Cases

2026-04-24 - 2029-07-31

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

  • Condition/Disease

    Pulmonary Arterial Hypertension

  • Test Drug

    吸入用膠囊劑

Participate Sites
3Sites

Recruiting3Sites

2024-10-01 - 2034-06-01

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-05-01 - 2030-12-31

Phase III

Not yet recruiting
A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas

  • Condition/Disease

    Extrapulmonary Neuroendocrine Cancer (epNEC)

  • Test Drug

    注射用凍晶粉末 注射用懸液劑 注射用懸液劑

Participate Sites
3Sites

Recruiting2Sites

2026-05-01 - 2034-12-31

Phase III

Active
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

  • Condition/Disease

    Myelodysplastic Syndrome、 Anemia

  • Test Drug

    皮下注射劑

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2026-05-01 - 2033-12-31

Phase III

Active
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    皮下注射劑 皮下注射劑

Participate Sites
6Sites

Recruiting6Sites

2026-06-01 - 2032-01-17

Phase III

Not yet recruiting
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

  • Condition/Disease

    Pancreatic Cancer、PDAC - Pancreatic Ductal Adenocarcinoma

  • Test Drug

    錠劑 靜脈輸注液 靜脈輸注液

Participate Sites
5Sites

Recruiting5Sites

2026-06-01 - 2032-12-31

Phase III

Not yet recruiting
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma

  • Condition/Disease

    High-risk Muscle Invasive Urothelial Carcinoma

  • Test Drug

    凍晶注射劑 注射劑 注射劑 注射劑

Participate Sites
6Sites

Not yet recruiting1Sites

2024-09-30 - 2028-11-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2024-10-01 - 2032-12-31

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2024-10-01 - 2032-12-31

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

1 24 25 26 27 28 226
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB